Vimarsana
Biggest News Aggregation in the World

Interim Safety News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Interim Safety. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Interim Safety Today - Breaking & Trending Today

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023 - Vimarsana News

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

Published: October 19, 2023

Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 -- Pliant Therapeutics, Inc. , a clinical-stage...

Source: marketscreener.com
Related Topics:
United StatesJohanna SchaubChristopher KeenanMichael TraunerRichard PencekTerry HornerGideonm HirschfieldChrisn BarnesHardeane AchneckChristoph SchrammGideon HirschfieldTheresa ThuenerKrisv KowdleyAnnie ClarkChristopherl BowlusPliant Therapeutics IncAutoimmune Liver Disease ResearchEuropean Medicines AgencyDrug AdministrationCorporate CommunicationsToronto Centre For Liver DiseaseAmerican AssociationLiver DiseasesPrimary Sclerosing CholangitisInterim Safety
Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical's Proprietary Suprachoroidal Space Platform Seite 1 - Vimarsana News

Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical's Proprietary Suprachoroidal Space Platform Seite 1

Published: October 4, 2022

04.10.2022 - - Favorable Safety Profiles and Encouraging Efficacy Data Reported in Clinical Trials in the Suprachoroidal Space (SCS) Across Multiple Therapeutic Areas using Clearside’s SCS Microinjector - - SCS Microinjector Featured in Multiple Oral and Poster ... Seite 1

Source: wallstreet-online.de
Related Topics:
United StatesThomasa CiullaDevelopment OfficerAura Biosciences IncSuprachoroidal AdministrationDrug AdministrationMeeting Of The American Academy OphthalmologyClearside Biomedical IncAmerican AcademyChief Medical OfficerChief DevelopmentInterim SafetyEfficacy DataOngoing Phase
Biogen Inc.: New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression - Vimarsana News

Biogen Inc.: New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression

Published: April 4, 2022

Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosingAdditional real-world data affirm high

Source: finanznachrichten.de
Related Topics:
United StatesUnited KingdomMaha RadhakrishnanCharles WeissmannWalter GilbertHeinz SchallerShibeshih BelachewAshleigh KossMike HenckeDiroximel FumarateKenneth MurrayProgram DatabaseCommitment To HealthBiogen Digital HealthSix Week AdministrationAcariahealth Specialty Pharmacy ProgramExchange CommissionAmerican Academy Of NeurologyMs With Digital Health ResearchAmerican AcademyChief Medical OfficerEvery Six WeekUnified CommitmentWorld Analyses Further Demonstrate High RatesContinues Pursuit
New Data at AAN 2022 Highlight Real-World Evidence from - Vimarsana News

New Data at AAN 2022 Highlight Real-World Evidence from

Published: April 4, 2022

Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every...

Source: globenewswire.com
Related Topics:
United StatesUnited KingdomMaha RadhakrishnanCharles WeissmannWalter GilbertHeinz SchallerShibeshih BelachewAshleigh KossMike HenckeDiroximel FumarateKenneth MurrayProgram DatabaseBiogen Digital HealthSix Week AdministrationBiogen IncResearch In Multiple SclerosisCommitment To HealthAcariahealth Specialty Pharmacy ProgramExchange CommissionAmerican Academy Of NeurologyMs With Digital Health ResearchEuropean Committee For TreatmentAmerican AcademyChief Medical OfficerEvery Six Week
Biogen Inc.: New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis - Vimarsana News

Biogen Inc.: New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

Published: October 13, 2021

MS PATHS data indicate that 100 percent of people with MS treated with natalizumab, interferons or fumarates achieved an antibody response following COVID-19 vaccinationData from this analysis also suggest

Source: finanznachrichten.de
Related Topics:
United KingdomUnited StatesJeffrey CohenMaha RadhakrishnanWalter GilbertCharles WeissmannHeinz SchallerAshleigh KossMike HenckeDiroximel FumaratePeginterferon BetaKenneth MurrayExchange CommissionAdministration In Black African AmericanPartners Advancing TechnologyResearch In Multiple SclerosisHealth SolutionsEuropean Committee For TreatmentEuropean CommitteeMultiple SclerosisCleveland ClinicChief Medical OfficerData Presentations FeaturedPeople Living With Multiple Sclerosis WithinReal World Adherence